Researchers in Vienna reported nail detachment in 39% of GLP-1 users versus 9% of non-users. Authors say the self-reported data shows a link, not proof of cause.
Recap by typeshit. Full story at Fox News.
One study cited by @fittrwithsquats put the risk of non-scarring hair loss about 40% higher with GLP-1 use, mostly telogen effluvium. Nail findings are less consistent.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Jay Goldberg of the Consumer Choice Center argues the $50 copay only covers some Medicare patients, and points to PBM reform and competition instead.
Lilly is appealing a court loss over whether retatrutide counts as a biologic. A win could mean 12 years of exclusivity instead of 5 and a later Medicare price fight.
Loading…